NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

肺癌手術的全球市場:各類型、產品、地區的成長率,趨勢及預測(2018年∼2023年)

Lung Cancer Surgery Market - Growth, Trends, and Forecasts (2020 - 2025)

出版商 Mordor Intelligence Pvt Ltd 商品編碼 390847
出版日期 內容資訊 英文 110 Pages
商品交期: 2-3個工作天內
價格
肺癌手術的全球市場:各類型、產品、地區的成長率,趨勢及預測(2018年∼2023年) Lung Cancer Surgery Market - Growth, Trends, and Forecasts (2020 - 2025)
出版日期: 2020年06月01日內容資訊: 英文 110 Pages
簡介

肺癌手術市場,預計從2018年到2023年的預測期間內,記錄約7%的年複合成長率。肺癌,特徵是肺組織內失控的細胞增生的致命性肺腫瘤。肺癌的解釋,透過支氣管鏡或CT引導進行的切片檢查確認。肺癌手術,是肺癌組織的外科切除。手術的種類,取決於腫瘤的大小及肺內位置。

本報告提供全球肺癌手術市場調查,整體市場趨勢,各類型、產品、地區的詳細趨勢,市場成長的影響要素分析,競爭情形,主要企業簡介等資訊彙整。

目錄

第1章 簡介

  • 市場定義

第2章 調查方法

第3章 摘要整理

第4章 主要影響要素

第5章 市場概要

  • 目前市場方案
  • 波特的五力分析
    • 供應商談判力
    • 消費者談判力
    • 新加入廠商的威脅
    • 替代產品與服務的威脅
    • 產業內的競爭

第6章 成長要素,阻礙因素,機會,課題分析(DROC)

  • 市場成長要素
    • 肺癌發病率的上升
    • 微創手術領域的技術進步
    • 大氣污染等級的上升
  • 市場阻礙因素
    • 有效的替代治療
  • 市場機會
  • 主要課題

第7章 市場區隔

  • 各類型
    • 部分切除術
    • 肺葉切除術
    • 肺切除
    • 袖切除術
  • 各產品
    • 外科設備
    • 螢幕設備
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東、非洲
    • 南美

第8章 競爭情形

  • M&A分析
  • 協定,合作,夥伴關係
  • 新產品的銷售

第9章 主要企業

  • Accuray
  • Ethicon
  • GE Healthcare
  • Johnson & Johnson
  • Olympus
  • Richard Wolf
  • Siemens Healthcare
  • 其他

第10章 市場未來展望

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 55305

Rising air pollution and people getting affected by it are one of the prime factors responsible for the growth of the market for lung cancer surgery. As per an article by the Vital Strategies Environmental Health Division staff, 2018, while most of the 4.2 million premature deaths linked to air pollution are due to heart disease and strokes, around 1.7 million deaths are from lung cancer and other respiratory diseases globally. According to the WHO database, levels of ultra-fine particles of less than 2.5 microns are highest in India, which has 16 of the world's 30 most polluted cities. Thus, a rise in air pollution is, primarily, driving the lung cancer rate, and hence the studied market is expected to be impacted.

Key Market Trends

Segmentectomy is Expected to Witness High Growth

With the growing prevalence of lung cancer and technological development, the therapy line has also been improved and people can start taking treatment from the early stage, these factors are expected to further boost the growth of the lung cancer surgery market.

Segmentectomy is a common surgical treatment that can be an option to treat non-small cell lung cancer (NSCLC). It is mostly recommended over lobectomy if the patient already has a highly reduced lung reserve. Although lung segmentectomy has always been popular for resection of supportive lesions and nonmalignant masses, most of the time it is recommended for very early lung cancer.

The growing popularity of this technique is because of better outcomes, less pain, and shorter recovery than traditional surgical techniques. Segmentectomy procedure has a good success rate for removing localized tumors and cancers with higher survival rates, with the retention of organ functions up to a certain degree and these advantages are anticipated to fuel the studied market growth.

However, there are some risks associated with segmentectomy arising from general anesthesia, which raises the chances of excessive bleeding, blood clot formation, pneumonia, and infection of the surgical wound.

North America is Expected to Dominate the Market

As per the American Cancer Society's estimation, the new cases of lung cancer in the United States for 2018 were around 234,030, and about 154,050 deaths were expected due to lung cancer. In the United States, lung cancer survival has been improved and the incidence of localized lung cancer has increased.

According to the American Lung Association (2018), approximately 541,000 Americans living today have been diagnosed with lung cancer at some point in their lives. The majority of lung cancer patients have been diagnosed within the last five years. Each year, around tens of thousands of people, are cured of non-small cell lung cancer (NSCLC) in the United States. Lung cancer is mostly a disease of the elderly. This indicates the burden of lung cancer in this country and this is resulting in the growth of the market studied as there is a high demand for cancer treatment in the United States.

Competitive Landscape

The lung cancer surgery market is moderately competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. However, with technological advancements and product innovations, mid-size to smaller companies are increasing their market presence, by introducing new products at cheaper prices.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing Burden of Lung Cancer
    • 4.2.2 Technological Advancements in the Field of Minimally Invasive Surgeries
    • 4.2.3 Rise in the Level of Air Pollution
  • 4.3 Market Restraints
    • 4.3.1 Effective Alternative Treatment
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Type
    • 5.1.1 Thoracotomy
      • 5.1.1.1 Lobectomy
      • 5.1.1.2 Sleeve Resection
      • 5.1.1.3 Segmentectomy
      • 5.1.1.4 Pneumonectomy
    • 5.1.2 Minimally Invasive Surgeries
  • 5.2 By Product
    • 5.2.1 Surgical Devices
    • 5.2.2 Monitoring Devices
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle-East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle-East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Accuray Incorporated
    • 6.1.2 GE Healthcare
    • 6.1.3 Johnson & Johnson
    • 6.1.4 Olympus Corporation
    • 6.1.5 Richard Wolf GmbH
    • 6.1.6 Siemens Healthineers AG
    • 6.1.7 AngioDynamics Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS